Floatz logo

PD-L1 CAR-T cells

Peritoneal Carcinoma Metastatic

Sichuan UniversityEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Peritoneal Carcinoma Metastatic cohort.

Asset / SponsorPhaseRating
Eloxatin
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3BB
FLUOROURACILUM
Ciusss de L'Est de l'Île de Montréal
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB
Irinotecan
Catharina Ziekenhuis Eindhoven
Phase 3BB

View all 42 →

Same molecule, other indications

PD-L1 CAR-T cells is also rated in:

Malignant AscitesDormant
CC
Indicative ·
43 / 100
View asset →
Pleural Effusion, MalignantDormant
C
Indicative ·
39 / 100
View asset →
HER2 Positive MalignanciesDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →